{
    "nct_id": "NCT06266299",
    "official_title": "A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating the Safety and Tolerability of Intravenous KK2269 Monotherapy and Combination Therapy With Docetaxel in Adult Participants With Solid Tumors",
    "inclusion_criteria": "* Key Common Inclusion Criteria for Parts 1 and 2:\n\n  * Patients who are ≥ 18 years old at the time of informed consent\n  * Patients who have disease measurable by RECIST v1.1\n  * Patients with an ECOG PS of 0 or 1\n  * Patients with a life expectancy of at least 3 months in the judgement of the investigator or subinvestigator\n  * The specified periods have passed respectively after the completion of previous cancer treatments as of the date of enrollment\n  * Patients who agree to use a medically effective method of contraception\n* Key Additional Inclusion Criterion for Part 1:\n\n  •Patients with histological or cytological evidence of at least one locally advanced or metastatic non-CNS solid tumor\n* Key Additional Inclusion Criteria for Part 2:\n\n  * Patients with histological or cytological evidence of any of the following disease:\n  * Gastric adenocarcinoma, GEJ adenocarcinoma, or esophageal adenocarcinoma\n  * NSCLC\n  * Patients who are suitable for docetaxel treatment\n* Key Common Exclusion Criteria for Parts 1 and 2:\n\n  * Patients with an uncontrolled or serious intercurrent illness\n  * Patients with known active central nervous system metastasis\n  * Patients with a history of ≥ Grade 3 allergic reaction to any antibody drug\n  * Patients with a history of autoimmune disease\n  * Patients with a history of HIV, HBV, or HCV at screening\n  * Patients who have a history of primary immunodeficiency\n* Key Additional Exclusion Criterion For Part 2:\n\n  * Patients with a history of treatment with docetaxel\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}